Sun, Jul 13, 2014, 9:49 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

CollabRx, Inc. Message Board

green_side_up 5 posts  |  Last Activity: Jun 27, 2014 6:06 PM Member since: Nov 2, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • green_side_up green_side_up Jun 27, 2014 6:06 PM Flag

    Look for a big move up in the next 1-2 months as cardiologists digest last week's news of the 40% lower risk by reducing triglycerides, a direct improvement seen from taking Vascepta. AMRN will see $2 shortly and finish 2014 around $5. Usually takes a few weeks for medical news to get around because not all physicians stay abreast of the latest medical news (sad, but true), scripts numbers will rise as the news changes how cardiologists treat patients. In the hands of big pharma, Vascepta would do extremely well. Expect a takeout.

  • green_side_up by green_side_up Jun 17, 2014 3:37 AM Flag

    Another press release of so-called positive news...a new patent, another cohort of its lead cancer drug, more uses for its new antibiotic, etc., etc., etc.

    CTIX goes nowhere. Market cap of $180 million despite three potential blockbuster drugs in development. Doesn't make much sense does it? Nope. And, that should raise a red flag. The market doesn't care about any of these types of press releases. The market wants to know whether any of these drugs work. And, so far, we don't know much of anything. Sure, Kevatrin is in its 8th cohort and is increasing its dosage...but there are plenty of things that could do a concoction of vitamins. The real and only question the market cares about is whether Kevatrin (and the other two drugs in the pipeline for that matter) is creating any statistically significant response rates among its patients. Until that time, all of this type of stuff is management fluff.

    And, let's also keep in mind that if Kevatrin was really the so-called magic bullet...and patients had amazing response rates, you can bet that somebody would hear about it before everyone else....somebody would buy a massive amount of this stock or the options. So, watch the volume...there will be a big pick-up in volume the day before great results are announced, if any, as the smart money will hear about the amazing recovery of John Smith from the hospital bed in Dana Farber and get into the stock before the press release carrying the information to the public. That's how things work.

    Ignore Ctixers fluff too...just watch the CTIX price and volume.

  • green_side_up by green_side_up May 9, 2014 11:09 AM Flag

    This stock is trading like both Einhorn and Loeb bailed...that's the problem with waiting for quarterly filings...we just don't know. But, the action is HORRIBLE. Need more insider buying ASAP!

  • Piper loved QURE on April 2nd and now the stock has been destroyed. I hate analysts who have no balls to re-iterate their BUY recommendations. This is a GIFT!

    U.S.-listed shares of Netherlands-based pharmaceutical company Uniqure (QURE) are rising after Baxter International (BAX) acquired Chatham Therapeutics, which is developing gene therapy treatments intended for patients with hemophilia. WHAT'S NEW: Baxter agreed to acquire all of Chatham’s outstanding membership interests and as a result will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia. Under the terms of the agreement, Baxter will make an initial payment of $70M to acquire all of the outstanding membership interests of Chatham and may make additional payments in the future. Baxter will continue the ongoing Phase I/II open-label clinical trial to assess the safety and optimal dosing schedule of hemophilia treatment BAX 335. ANALYST REACTION: Research firm Piper Jaffray said the Baxter acquisition has a positive read-through for Uniqure. The deal validates other hemophilia gene therapy programs in development, most notably Uniqure's, according to the firm. Analyst Joshua Schimmer wrote that there are other gene therapy programs for hemophilia in development beside Uniqure's and Baxter's, but he believes Uniqure has an advantage since it will be important to be among the first to market. The analyst also said that the market is large enough to accommodate more than one gene therapy option. Piper reiterated its Overweight rating and $35 price target on Uniqure. OTHERS TO WATCH: Other companies noted by Piper as currently offering hemophilia treatments or working on hemophilia therapies include Pfizer (PFE), Novo Nordisk (NVO), Biogen (BIIB), Sangamo (SGMO) and BioMarin (BMRN). PRICE ACTION: During late morning trading, shares of Uniqure rose 77c or 4.92% to $16.43, while Baxter slid 33c, or 0.45%, to $73.

  • green_side_up green_side_up Apr 14, 2014 2:44 PM Flag

    ISIS did perfectly well without Novatis when it left it's partnership back in 2000. Novartis hasn't been a big RNAi player in over 14 years. Given that it is in cost cutting mode, this announcement is no surprise. I would buy ISIS, ROSG, and TKMR on this news as all are down a lot.

    Sentiment: Strong Buy

1.88-0.03(-1.57%)Jul 11 3:58 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.